Advanced search
Publication Cover
Acta Oto-Laryngologica Volume 140, 2020 - Issue 2
Submit an article Journal homepage
142
Views
10
CrossRef citations to date
0
Altmetric
Salivary glands

Programmed death ligand-1 expression is associated with stage and histological grade of parotid carcinoma

Masaaki HigashinoDepartment of Otorhinolaryngology - Head and Neck Surgery, Osaka Medical College, Takatsuki, Japan; ORCID Iconhttp://orcid.org/0000-0002-9905-5102
ORCID Icon,
Ryo KawataDepartment of Otorhinolaryngology - Head and Neck Surgery, Osaka Medical College, Takatsuki, Japan; Correspondence[email protected]
,
Shuji NishikawaDepartment of Otorhinolaryngology - Head and Neck Surgery, Osaka Medical College, Takatsuki, Japan;
,
Tetsuya TeradaDepartment of Otorhinolaryngology - Head and Neck Surgery, Osaka Medical College, Takatsuki, Japan;
,
Shin-Ichi HaginomoriDepartment of Otorhinolaryngology - Head and Neck Surgery, Osaka Medical College, Takatsuki, Japan;
,
Yoshitaka KurisuDepartment of Pathology, Osaka Medical College, Takatsuki, Japan
&
Yoshinobu HiroseDepartment of Pathology, Osaka Medical College, Takatsuki, Japan
 show all
Pages 175-180 | Received 05 Aug 2019, Accepted 12 Oct 2019, Published online: 16 Jan 2020

References

  • Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–1867.
  • Spiro RH. Salivary neoplasms. Overview of a 35-year experience with 2,807 patients. Head Neck. 1986;8(3):177–184.
  • Renehan A, Gleave EN, Hancock BD, et al. Long-term follow-up of over 1000 patients with salivary gland tumours treated in a single center. Br J Surg. 1996;83(12):1750–1754.
  • El-Naggar AK, Chan JKC, Grandis JR, et al. WHO classification of head and neck tumours. 4th ed. Lyon (France): IARC. 2017. p. 159–202.
  • Cohen RB, Delord JP, Doi T, et al. Pembrolizumab for the treatment of advanced salivary gland carcinoma. Findings of the phase 1b keynote-028 study. Am J Clin Oncol. 2018;41:1083–1088. doi.10.1097/COC.0000000000000429.
  • Ellis GL, Auclair PL. AFIP atlas of tumor pathology series 4. Tumors of the salivary glands. 4th series. Washington (DC): Armed Forces Institute of Pathology; 2008. p. 27–48.
  • Nishikado A, Kawata R, Haginomori SI, et al. A clinicopathological study of parotid carcinoma: 18-year review of 171 patients at a single institution. Int J Clin Oncol. 2018;23(4):615.
  • Lima RA, Tavares MR, Dias FL, et al. Clinical prognostic factors in malignant parotid gland tumors. Otolaryngol Head Neck Surg. 2005;133(5):702–708.
  • Jouzdani E, Yachouh J, Costes V, et al. Prognostic value of a three-grade classification in primary epithelial parotid carcinoma: result of a histological review from a 20-year experience of total parotidectomy with neck dissection in a single institution. Eur J Cancer. 2010;46(2):323–331.
  • Rimm DL, Han G, Taube JM, et al. A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer. JAMA Oncol. 2017; 3(8):1051–1058.
  • Herbst RS, Baas P, Perez-Gracia JL, et al. Pembrolizumab vs docetaxel for previously treated NSCLC (KEYNOTE-010): archival vs new tumor samples for PD-L1 assessment. J thorac oncol. 2016;11(10):S242–S243.
  • Ilie M, Long-Mira E, Bence C, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol. 2016; 27(1):147–153.
  • Wu P, Wu D, Li L, et al. PD-L1 and survival in solid tumors: a meta-analysis. PLoS ONE. . 2015; 10(6):e0131403.
  • Muenst S, Schaerli AR, Gao F, et al. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2014;146(1):15–24.
  • Mukaigawa T, Hayashi R, Hashimoto K, et al. Programmed death ligand 1 expression is associated with poor disease free survival in salivary gland carcinomas. J Surg Oncol. 2016;114(1):36–43.
  • Harada K, Ferdous T, Ueyama Y. PD-L1 expression in malignant salivary gland tumors. BMC Cancer. 2018;18(1):156.
  • Kim HR, Ha SJ, Hong MH, et al. PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients. Sci Rep. 2016; 14(6):36956.
  • Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012; 4:127–137.
  • Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–2028.
  • Chow LQM, Haddad R, Gupta S, et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. JCO. 2016;34(32):3838–3845.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.